Skip to main content

6 Result(s)

within R Delarue Remove this filter

and

  1. Article

    Actualités en hématologie

    R. Delarue, C. Gisselbrecht in Oncologie (2011)

    Download PDF (819 KB)

  2. No Access

    Article

    Neutropénie et risque infectieux sous rituximab

    Rituximab is associated with late-onset neutropenia, which occurs after the end of therapy. This side effect was initially considered a rare phenomenon, but recent studies have suggested an incidence rate betw...

    R. Delarue in Oncologie (2011)

  3. No Access

    Article

    The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

    A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n=51) were ...

    F Lefrère, S Zohar, D Ghez, R Delarue, F Audat, F Suarez… in Bone Marrow Transplantation (2006)

  4. No Access

    Article

    Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update

    F Lefrère, V Lévy, S François, R Delarue, N Ifrah, H Tilly, F Valensi… in Leukemia (2004)

  5. No Access

    Article

    Thalidomide therapy induces response in relapsed mantle cell lymphoma

    G Damaj, F Lefrère, R Delarue, B Varet, R Furman, O Hermine in Leukemia (2003)

  6. No Access

    Article

    T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome

    <p>Nijmegen breakage syndrome (NBS) is characterized by growth retardation, microcephaly, mental retardation, immunodeficiency, and predisposition to malignancies, especially B-cell lymphomas. In contrast, leu...

    A.-S. Michallet, G. Lesca, I. Radford-Weiss, R. Delarue, B. Varet… in Annals of Hematology (2003)